The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma

To detect the relationship of the epidermal growth factor receptor (EGFR) mutation status and the clinicopathologic features. Six hundred thirty-three patients with pathologically confirmed lung adenocarcinoma who underwent lung cancer resection surgery at the Fourth Hospital of Hebei Medical University between April 2012 and April 2015 were selected for the study. The 32 types of mutations in exons 18-21 of the EGFR gene were detected. The total EGFR mutation rate among patients with lung adenocarcinoma was 56.9%. The mutation rates were 71.2% among females and 42.8% among males (P < 0.05). Among patients with TNM stage I, II, III, and IV disease, the EGFR mutation rates were significant differences (P < 0.05). Concerning different subtypes of lung adenocarcinoma, the EGFR mutation rates were differences, and these differences were statistically significant (P < 0.05). Cox multivariate regression model analysis considering EGFR mutation status revealed that differences in TNM stage (P < 0.01), smoker status, and tumor size were statistically significant predictors. Patients with minimally invasive and lepidic adenocarcinomas were categorized as low-risk group with high EGFR mutation rate; Patients with micro-papillary and solid adenocarcinomas were categorized as high-risk with lower EGFR mutation rate, so there are different mechanisms in different types of adenocarcinomas.